Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial.

Baraliakos X, Pournara E, Gossec L, Mease PJ, White R, O'Brien E, Schulz B, Marzo-Ortega H, Coates LC

Open source

DOI
10.1136/rmdopen-2022-002303
Published
2022 Jul
Container
RMD open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/rmdopen-2022-002303,
  title = {Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial.},
  author = {Baraliakos X and Pournara E and Gossec L and Mease PJ and White R and O'Brien E and Schulz B and Marzo-Ortega H and Coates LC},
  year = {2022},
  journal = {RMD open},
  doi = {10.1136/rmdopen-2022-002303},
  url = {https://doi.org/10.1136/rmdopen-2022-002303}
}

RIS

TY  - JOUR
TI  - Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial.
AU  - Baraliakos X
AU  - Pournara E
AU  - Gossec L
AU  - Mease PJ
AU  - White R
AU  - O'Brien E
AU  - Schulz B
AU  - Marzo-Ortega H
AU  - Coates LC
PY  - 2022
JO  - RMD open
DO  - 10.1136/rmdopen-2022-002303
UR  - https://doi.org/10.1136/rmdopen-2022-002303
ER  - 

APA

X, B., E, P., L, G., PJ, M., R, W., E, O., B, S., H, M., & LC, C. (2022). Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial.. RMD open. https://doi.org/10.1136/rmdopen-2022-002303

Source records